High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation in relapsed/refractory marginal zone non-Hodgkin' s lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 595-597, 2012.
Article
Dans Chinois
| WPRIM
| ID: wpr-473202
ABSTRACT
Objective To evaluate the role of high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation in relapsed/refractory marginal zone lymphomas. Methods The transplant database was reviewed retrospectively from Tianjin Medical University Cancer Hospital identified 12 patients who underwent high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation. Results Among the twelve patients who underwent autologous hematopoietic stem cell transplantation, the median duration of progression-free survival (PFS) was 104 months and the median duration overall survival (OS) was 117 months; 6 patients were still alive with disease-free. Conclusion High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation is feasible to patients with relapsed/refractory marginal zone lymphomas, particularly to those insensitive to rituximabincluded combined chemotherapy.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Journal of Leukemia & Lymphoma
Année:
2012
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS